New data presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting suggest a potential shift in how clinicians approach recurrent ovarian cancer. Results from a Phase 2 trial indicate that combining the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx—marketed as ELAHERE—with standard carboplatin chemotherapy may offer a strong response for patients with platinum-sensitive ovarian cancer (PSOC).
The findings, stemming from the IMGN853-0420 trial, are particularly significant because they target a critical gap in the treatment continuum. Even as patients with platinum-sensitive disease typically respond to chemotherapy, that responsiveness often wanes with each subsequent recurrence, leaving many with dwindling options and cumulative toxicity. The leverage of mirvetuximab soravtansine for platinum-sensitive ovarian cancer represents an effort to integrate targeted therapy earlier in the treatment cycle to maintain disease control.
In the study, which enrolled 125 patients with folate receptor alpha (FRα)-positive disease, the combination of ELAHERE and carboplatin followed by ELAHERE monotherapy yielded a confirmed objective response rate (ORR) of 62.7% in the subgroup of patients with high FRα expression (≥50%). Across the overall study population, the ORR remained similarly strong at 62.4%.
Breaking the Cycle of Diminishing Chemotherapy Returns
For many women facing recurrent ovarian cancer, the standard of care has long been a cycle of platinum-based chemotherapy. However, as noted by Daejin Abidoye, M.D., vice president and therapeutic area head of oncology at AbbVie, these responses often diminish over time. This “platinum-sensitive” window is a race against the clock before the cancer potentially becomes platinum-resistant.
The IMGN853-0420 trial tested a “hit hard, then maintain” strategy. Patients received the ADC and carboplatin every three weeks for six to eight cycles. Following this induction phase, 81% of participants showed no disease progression and were able to transition to single-agent mirvetuximab soravtansine as a continuation therapy. This transition proved effective, with the ORR reaching 68% among those who moved to monotherapy.
The duration of response (DoR) across the overall population was a median of 11.2 months, suggesting that the combination may provide more than just a temporary shrink in tumor size, but a meaningful period of stability.
Addressing the PARP Inhibitor Challenge
One of the most challenging cohorts in gynecologic oncology is the patient population previously treated with polymerase inhibitors (PARPi). These patients often experience a reduced response to subsequent platinum-based chemotherapy, creating an urgent need for alternative mechanisms of action.
Nearly half of the participants in this trial had prior PARPi exposure. Despite this history, the response rate for this specific group was 63.9%. This suggests that the FRα-targeted approach may bypass some of the resistance mechanisms developed during PARP inhibitor therapy, providing a viable path forward for patients who previously had limited options.
| Patient Group | Objective Response Rate (ORR) | Clinical Context |
|---|---|---|
| High FRα Expression (≥50%) | 62.7% | Primary study endpoint subgroup |
| Overall Population (≥25% FRα) | 62.4% | General FRα-positive cohort |
| Prior PARPi Exposure | 63.9% | Patients with previous inhibitor therapy |
| Monotherapy Transition | 68% | Patients continuing after combination |
Navigating the Safety Profile and Ocular Toxicity
As a physician, We see important to contextualize these efficacy numbers with the drug’s safety profile. Mirvetuximab soravtansine is an antibody-drug conjugate, a “smart bomb” designed to deliver a potent tubulin inhibitor directly to cells expressing the folate receptor alpha. While this precision reduces some systemic side effects, it introduces specific class-related toxicities, most notably in the eyes.
The trial reported that the safety profile remained consistent with previous ELAHERE studies. The most frequent treatment-related adverse events were low-grade ocular issues, including corneal changes. Importantly, these events were reversible in more than 90% of patients, typically managed with steroid and lubricating eye drops.
However, the study did record several Grade 3 or higher adverse events that required close clinical monitoring. These included neutropenia (15%), blurred vision (10%), and thrombocytopenia (10%). Other notable Grade 3+ events occurred at a 5% to 6% rate, including cataracts, dry eye, diarrhea, and peripheral sensory neuropathy.
“These findings support further investigation of a novel treatment approach that integrates antibody drug conjugates with standard chemotherapy in patients with folate receptor alpha (FRα)-expressing recurrent platinum‑sensitive ovarian cancer,” said Gottfried E. Konecny, M.D., Professor of Medicine at the David Geffen School of Medicine at UCLA and primary investigator of the study.
What This Means for the Treatment Continuum
Currently, ELAHERE is indicated for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already failed several prior systemic treatments. The move into the platinum-sensitive space is a strategic expansion, aiming to treat the disease earlier and potentially prolong the time before a patient becomes fully resistant to chemotherapy.
While these Phase 2 results are encouraging, the combination of mirvetuximab soravtansine-gynx and carboplatin is not yet approved for use in platinum-sensitive ovarian cancer in the U.S. Or E.U. The results serve as a proof-of-concept that ADCs can be integrated with traditional chemotherapy to enhance the depth and duration of response.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their oncology team to determine the most appropriate treatment plan for their specific diagnosis.
The full data set is being presented during the Rapid-Fire Oral III: Translational and ADC session at the Society of Gynecologic Oncology Annual Meeting in San Juan, Puerto Rico, which concludes on April 13, 2026. Future clinical trials will likely focus on comparing this combination against standard-of-care chemotherapy alone to determine if it significantly improves overall survival.
We invite readers to share their thoughts or questions about these developments in the comments below.
